13 Hrs_1777294112963_722751297.jpg&w=48&q=75)
Source:
الأنباء
الأنباء
Ready to play
Ready to play
The results of the third phase of the Ritatrotaid drug, which treats obesity and type 2 diabetes, showed significant success in weight loss and blood sugar improvement. The medication achieved an average weight reduction of up to 28.3% after 80 weeks and lowered HbA1c levels by 2% over 40 weeks. With promising data available, the drug is still under study and has not yet been officially approved for use.
Notice: This Is an AI-Generated Summary
Comments (0)